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ABSTRACT
NOTCH DRIVES PROLIFERATION AND RADIATION RESISTANCE OF CANCER
STEM CELLS IN ADENOID CYSTIC CARCINOMA. Michael T. Chang, Alex
Panaccione, Beatrice E. Carbone, Christopher A. Moskaluk, Sergey V. Ivanov, Wendell
G. Yarbrough. Section of Otolaryngology, Department of Surgery, Yale University,
School of Medicine, New Haven, CT.
Adenoid cystic carcinoma (ACC) of the salivary gland is an indolent but highly lethal
neuroinvasive tumor with a propensity for radiation resistance, recurrence, and
metastasis. Molecular understanding of this rare tumor has been hampered by the absence
of validated in vitro models and a limited number of xenografts. Therapeutic options for
ACC are limited to surgery and radiation and are associated with an unacceptably low
rate of cure. Cancer stem cells (CSC) are an attractive therapeutic target, and
understanding their role in ACC may advance therapy. Our objectives were: 1) to
establish and validate ACC cell cultures, 2) to determine if CSC exist in ACC, and if so,
isolate and characterize these cells in ACC, and 3) to identify new therapeutic targets for
ACC. To culture ACC and to isolate and initially characterize CSC from ACC, we
modified a ROCK inhibitor-based cell culture technique, identified CD133 (PROM1) as a
cell surface marker of CSCs, and used immunomagnetic cell sorting to separate and
characterize RNA and protein expression in these cells. We found that CD133+ cells
expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice
more readily than CD133- cells. Depletion of NOTCH1 and SOX10 in cultured ACC
induced death of CD133+ cells, indicating their essential roles in maintenance of
stemness. An inhibitor of Notch activation, DAPT, selectively depleted CD133+ cells in
vitro, sensitized CD133+ cells to radiation, and inhibited growth of ACC tumor in vivo.
These results establish the presence of a previously uncharacterized population of
CD133+ cells with neural stem properties in ACC whose survival is dependent on
NOTCH1 and SOX10.

Sensitivity of ACC cells to Notch inhibition offer new

opportunities for targeted therapy in this orphan tumor.
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INTRODUCTION
Adenoid Cystic Carcinoma Overview
Background
Adenoid cystic carcinoma (ACC) comprises approximately one quarter of all
salivary gland malignancies and is one of the most relentless, unpredictable, and fatal
cancers of the head and neck region. First documented by French physicians Robin and
Lalboulbene in their 1853 publication Memoire sur trois productions morbides
nondescrites [Memoirs of three undescribed morbid productions], the mysterious and
lethal nature of this disease was evident even in its earliest descriptions (1). In 1859,
Prussian surgeon Theodor Billroth termed this disease “cylindroma,” naming it for its
characteristic histological appearance of cylindrical clusters of cells (2). Also noting its
distinct histology, Spies is credited with coining the term “adenoid cystic carcinoma” in
1930 (3), a term popularized in the medical community in 1953 when Foote and Frazell
classified several salivary gland tumor types in their seminal Cancer article (4). They
were also the first to note that ACC spanned a wider spectrum of histological types in
addition to its classic tubular appearance.
Since the earliest reports of ACC, physicians have noted several hallmark
characteristics, including its tendency to involve nerves (4), recur (2), metastasize, and
ultimately kill patients (5). In 1974, Conley and Dingman noted ACC to be “one of the
most biologically destructive and unpredictable tumors of the head and neck” (5). Despite
numerous clinical trials involving multiple treatment modalities and pharmaceutical
agents over the past several decades, ACC remains a very difficult disease to treat today.
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Epidemiology
While salivary gland malignancies are relatively rare, ACC represents a
significant portion (22%) of these cancers (6). Worldwide yearly incidence is estimated
to be 1 to 1.3 cases per 100,000 people, translating to roughly 1,200 new cases per year in
the US, making ACC the second most common salivary gland malignancy overall behind
mucoepidermoid carcinoma (7).
In the parotid gland, ACC is the second most commonly occurring cancer type,
occurring in 7-18% of cases, however ACC is the most common cancer type in the
sublingual gland (20%), submandibular gland (20%), and minor salivary glands (35-58%)
lining the upper aerodigestive tract (7-10). While most often found in the minor salivary
glands of the tongue, buccal mucosa, and palate (7, 9), ACC has also been reported to
occur in other sites of the airways, including the paranasal sinuses, lips, larynx, trachea,
and nasolacrimal tract (11). Outside of the aerodigestive tract, ACC has been reported to
arise in other glandular structures, including the breast (12), prostate (13), skin (14), and
female genital tract (15).
Salivary ACC typically affects people in their 5th or 6th decade of life, with a
mean age of 57 years (16). ACC has a slight tendency to occur in females (59%), and
approximately 80% of reported cases occur in Caucasians (16). Familial history, toxic
exposures, or environmental exposures have not been associated with increased risk of
ACC (16, 17).
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Clinical Behavior
The classical behavior of ACC is somewhat paradoxical: growth is slow and
indolent, but the cancer is relentless and progressive (11). Initially, ACC most commonly
presents as a firm mass in the head or neck region that slowly enlarges over months to
years. Depending on its location, the mass may occasionally present with pain, numbness
or ulceration (18). Given its tendency to invade nerves, ACC of the parotid gland can
present with facial nerve paralysis in up to one third of patients (9).
The tumor’s slow growth often leaves it amenable to surgical removal, however
local recurrences occur frequently, estimated in 16-39% cases (11, 18). Unlike other head
and neck cancers, regional lymph node metastases of ACC to the neck rarely occur, seen
in less than 10% of cases (19). However, distant metastases occur in 35-50% of cases,
most commonly to the lung (20). ACC also spreads to the bones, liver, and central
nervous system (20, 21). Complications resulting from distant metastases are often the
cause of death, with a mean time between lung metastases detection and death of 32.3
months, and a mean time between other metastatic site detection and death of 20.6
months (22).

Diagnosis
Fine needle aspiration (FNA) is the most widely used diagnostic tool in the initial
evaluation of a head and neck mass suspicious for neoplasm. Cytologic diagnosis is
possible in most cases, with FNA accurately identifying about 77% of ACC cases (23).
Cytologic analysis for ACC typically shows basaloid tumor cells clustered around
globules containing eosinophilic extracellular matrix material (23). Clinicians must be
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careful to distinguish ACC from pleomorphic adenoma, the most common benign tumor
of the salivary gland, as the two can have a very similar cytologic appearance. Largely
because of the cytologic similarity between ACC and benign tumors, the false negative
rate for FNA is 17%, therefore clinicians must interpret FNA results in the context of
other clinical findings (23).
Radiographic imaging by computed tomography (CT) or magnetic resonance
imaging (MRI) is used for evaluating the extent of tumor spread. MRI with gadolinium
contrast is important in assessing for nerve involvement. ACC tumors tend to have poorly
defined borders and homogeneous enhancement on T1-weighted MRI imaging, however
there are no objective radiographic signs specific to ACC versus other salivary tumor
types (24). Final diagnosis is made from histopathological analysis of a resected
specimen.

Histopathology
ACC is composed of two cell types within the salivary gland: myoepithelial cells
and ductal cells (9). Classically, there are three histological subtypes of ACC: cribiform,
tubular, and solid. Cribiform is the most common histology and is predominantly
composed of “punched out” pseudocysts amongst small ductal cell islands. Tubular
histology shows a palisading pattern of well-formed ducts lined by myoepithelial cells.
Solid histology involves solid sheets of both cell types with thin strands of intervening
stroma. Solid histology has historically been associated with a worse prognosis (25);
however, later studies have shown that tumor stage rather than histologic grade is a more
accurate prognostic indicator (26). While classically these histological subtypes have
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been viewed as distinct, the majority of tumors contain a mixture of these patterns (9). In
all subtypes, perineural invasion is very common (60% of cases), even in early stage
tumors (27).
Immunohistochemical (IHC) stains aid in the diagnosis of ACC. Characteristic
expression for ACC includes carcinoembryonic antigen (CEA), muscle specific actin
(MSA), Ki-67, and several cytokeratins (28). ACC stains very similarly to another lowgrade cancer, polymorphous low grade adenocarcinoma (PLGA); however, cellular
atypia and high Ki-67 index can assist in identifying ACC (9). Despite the histological
appearance of a low-grade cancer, all cases of ACC are considered high-grade salivary
gland neoplasms given the aggressive clinical behavior.

Management
For ACC of a major salivary gland, surgical excision of the entire involved gland
is the primary treatment option. Treatment of minor salivary gland tumors depends on
location, with oral cavity lesions typically being excised and lesions closer to the skull
base undergoing endoscopic removal or gamma knife therapy. Negative margins are
important to obtain, as margin status has been shown to be a significant predictor of local
recurrence (29). Interestingly, however, margin status has no significant bearing on rate
of distant metastasis (29). Because regional lymph node metastases are relatively rare in
ACC, neck dissections are typically reserved for cases where there is clinical evidence of
neck node metastasis (19).
Postoperative radiotherapy is often employed, as studies have shown it to
significantly improve local control for both early and late stage tumors (27); however,
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opposing studies have found that postoperative radiation does not significantly affect
local control except in advanced stages or cases with positive margins (30, 31).
Importantly, the addition of radiation has no significant effect on rates of distant
metastasis or overall survival (27, 30). Despite treatment with postoperative radiotherapy,
radiation resistance remains an issue as local recurrence occurs in approximately onethird of cases (11, 18).
To date, no systemic agents have been shown to induce a significant response in
the treatment of ACC, thus chemotherapy is typically reserved for palliative measures in
unresectable or metastatic disease (32).

Prognosis
The 5-year overall survival is 85-90%, however the 15-year overall survival rate
is 35-40% (25, 27, 30), reflective of a protracted clinical course typical of ACC. Factors
associated with worse prognosis include positive resection margins, major nerve
involvement, and advanced stage (27, 33). While it is possible for patients to live many
years with this indolent cancer, long-term disease-free survival is dismal being only 42%
at 5 years and 29% at 10 years (34). The majority of ACC cases end with death resulting
from complications of metastatic disease (22).

Molecular Landscape of ACC
Mutational Profile
Because the molecular drivers of ACC remain largely unknown, next-generation
sequencing methods have been employed to elucidate its mutational landscape. Three

7
recent studies performed genome and whole exome sequencing, looking at a combined
108 ACC specimens with matched normal DNA (35-37). All studies found a very low
somatic mutation rate, with one analysis reporting 13 mutations per exome (35), and
another study reporting a mean of 22 somatic mutations per sample, correlating to a nonsilent mutation rate of 0.31 mutations per megabase (36). ACC was also found to have a
highly diverse mutational profile, with mutations seen in chromatin state regulators, DNA
damage pathways, and growth factor signaling.
All studies identified t(6;9) fusions of the MYB-NFIB genes, as well as somatic
mutations in the MYB gene, aberrations seen in the majority of ACC cases (38). The
t(6;9) MYB-NFIB fusion has historically been the most commonly cited marker of ACC,
as it is unique to this tumor compared with other head and neck cancers (38). Recently, a
t(8;9) fusion of another MYB family member, MYBL1, and NFIB has been identified in
approximately 30% of t(6;9)-negative cases (39). MYB is a transcription factor with a
plethora of targets and acts to both activate and inhibit transcription of its targets.
Activation of MYB has several downstream effects including cellular proliferation and
inhibition of terminal differentiation, thus it is hypothesized that the translocation induces
pathologic changes of these cellular processes (40). MYB alterations have a significant
association with recurrence and metastasis (39), and the common presence of mutations
and fusions of MYB family members suggest that activation of this pathway is critical, if
not required, in development or maintenance of ACC.
Whole exome sequencing also found mutations in the FGF/IGF/PI3K pathway in
30% of cases (36). Moreso, samples with phosphatidylinositol 3-kinase (PI3K) mutations
were all from solid histology tumors, traditionally seen as the most aggressive variant of
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ACC. Fibroblast growth factors (FGF) and insulin-like growth factors (IGF) are known to
be potent oncogenic activators of PI3K (41). Further research into this pathway may
present a potentially promising therapeutic target for a subset of ACC cases.

Expression Changes
To identify differentially expressed genes involved in ACC formation or
maintenance, microarray gene expression analyses surveyed 8920 genes in 15 ACC
specimens and 5 normal salivary glands (42). Given the myoepithelial origin of the
tumor, it was not surprising that several genes involved in myoepithelial differentiation
are upregulated in ACC. Notable genes that are highly overexpressed included SOX4, a
transcription factor involved in neural and immunologic cell development, AP-2γ, an
upstream effector of oncogene c-Kit, and casein-kinase 1ε and frizzled-7, both members
of the Wnt/β-catenin pathway (42).
IHC examination of 27 ACC specimens found c-Kit (CD117) overexpression in
90% of ACC cases (43). c-Kit is a tyrosine kinase receptor involved in numerous
physiologic processes including hematopoiesis, spermatogenesis, and cell migration (44)
and is a transcriptional target of MYB (45). c-Kit is a known oncogenic driver in other
types of cancers such as seminomas and gastrointestinal stromal tumors (GISTs) (46, 47),
and c-Kit inhibition results in dramatic regression of GISTs (48). In ACC, c-Kit levels are
associated with poorer prognosis (43). Interestingly, c-Kit has been used to isolate
salivary progenitor cells, suggesting it may play a role in stem cell maintenance in ACC.
Though initially promising, however, tyrosine kinase inhibitors of c-Kit have failed to
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induce a therapeutic response in several clinical trials treating patients with ACC (49,
50).
SOX10, a transcription factor required for maintenance and migration of neural
crest stem cells, is also highly expressed in both primary ACC specimens and ACC
xenografts compared with normal salivary tissue and other salivary tumor types (51).
Microarray analyses indicating high SOX10 expression in ACC was confirmed by IHC.
In silico analysis identified genes co-expressed with SOX10 and defined the SOX10 gene
signature as unique to ACC compared with other salivary gland malignancies (51).
Interestingly, SOX10 is also expressed in basal-type breast carcinoma specimens as
confirmed by IHC, and components of the larger SOX10 gene signature are preserved in
basal-like breast cancers. The required role for SOX10 in neural crest stem cells, the
derivation of myoepithelial cells from neural crest, and the involvement of myoepithelial
cells in ACC and basal-like breast cancer suggest that SOX10 may play a critical role in
supporting the stem cell features in ACC and a subset of breast cancer, as well as other
cancers containing neural crest derivatives (51).
Fatty-acid binding protein 7 (FABP7), normally a chaperone for lipids between
cytoplasm and nucleus, is part of the SOX10 signature and is highly overexpressed in
microarray studies of ACC xenografts versus normal salivary glands (52). In ACC,
FABP7 is highly expressed in myoepithelial cell nuclei, suggesting a potential role in
development or proliferation of ACC, as nuclear FABP7 is present in rapidly
proliferating cells of other cancers (53, 54). Although the precise role of FABP7 in ACC
development or maintenance is not known, its expression correlates with aggressive
behavior and poor prognosis in ACC (52). In other cancers of neural crest derivatives
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such as glioma, FABP7 has been implicated as a critical player in stem cell maintenance
(55), and the presence of nuclear FABP7 is associated with poorer prognosis compared to
cytoplasmic FABP7 (53). The biological consequences have not been well characterized,
however FABP7 has been identified as a target of Notch signaling (56). As understanding
of the Notch pathway in ACC becomes better understood, so may the role of FABP7.

Epigenetic Alterations
Given the overall low mutational load in ACC and the relatively high number of
mutations involving chromatin regulators (37), it is likely that epigenetic changes play
critical roles in driving ACC. Analysis of CpG island DNA methylation levels in 16 ACC
specimens with matched normal tissue (57) revealed hypermethylated genes including
initiators of apoptosis or differentiation such as BCL2L11, transcription factors such as
EN1, GBX2, FOXL1, and NR2F2, and effectors of metabolism including XRN2, INSRR,
and PNLIPRP1, suggesting that epigenetic silencing of these genes may play an
important role in ACC. Significant hypomethylated genes in ACC include DOCK1,
involved in cell surface extension, and PARVG, involved in cell adhesion (57). The
biological consequences of these epigenetic changes require further study to determine
their functional significance and possible therapeutic implications.

Notch Signaling in ACC
Notch signaling is a highly conserved pathway that mediates cellular
differentiation and growth. Canonical Notch signaling is initiated by five ligands, Deltalike 1 (DLL1), DLL3, DLL4, Jagged-1 (JAG1), and JAG2 that bind to Notch receptors
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and trigger proteolytic cleavage by gamma-secretase. Notch cleavage releases the Notch
intracellular domain (NICD) that translocates to the nucleus where it imposes its
regulatory activity as a transcription factor (58). NOTCH can serve as an oncogene like it
does in breast cancer and T-cell acute lymphoblastic leukemia (58, 59), or as a tumor
suppressor, like in squamous cell carcinoma of the head and neck (HNSCC) (60). The
specific role of Notch signaling in ACC has yet to be fully elucidated.
Gene expression comparison between ACC and normal salivary tissue identified
that several genes in the Notch signaling pathway such as NOTCH3 and JAG1 were
highly expressed in cancers (42). In addition, NOTCH1 mutations were found in ACC
xenografts (58), and these exonic mutations are known to induce ligand-independent
release of NICD or stabilize the active NICD through deletion of the C-terminal PEST
domain. Interestingly, NOTCH1 activation, as measured by NICD, predicts response to
gamma-secretase inhibitors in breast cancer and ACC models (58). Further supporting a
role for Notch activation in ACC, whole exome sequencing identified missense or
truncating mutations in NOTCH1 and NOTCH2 in a low number of primary tumors,
though functional consequences of these NOTCH mutations were not determined in these
particular cases (35). As the role of Notch signaling in ACC becomes clearer, more
therapeutic opportunities for ACC may open, especially as Notch inhibition becomes an
increased focus of pharmaceutical companies.
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In Vitro and In Vivo Tools for ACC Research
Cell Lines
Particularly in rare cancers where original tumor tissue is scarce, reliable in vitro
models can play a critical role in the study of its molecular and biological properties, as
well as testing of potential therapeutic agents. At one point, several cell lines exchanged
by many academic institutions were used to study ACC, including ACC2, ACC3,
ACCM, ACCS, ACCNS, and CAC2. However, in 2009, short tandem repeat (STR) DNA
fingerprint analysis examining eight loci of nucleotides was performed with crossreferencing of these lines with national databases (61). Unfortunately, all six cell lines
were either improperly identified as ACC or contaminated. ACC2, ACC3, and ACCM
were found to be HeLa cells, ACCS were T24 urinary bladder cancer cells, ACCNS were
mouse cells, and CAC2 were rat cells (61). Misidentification of these cell lines nullified
the validity of all work derived from these cell lines, and since then, researchers have had
a great need for new in vitro tools to study ACC.
After the devastating results disqualifying previous ACC cell lines, another cell
line, SACC-83, derived from a minor salivary gland cancer has been described. Passage
of this cell line through a mouse was used to derive a line with higher metastatic
potential, SACC-LM (62, 63). STR analysis has shown that these cells are distinct from
HeLa cells, however a comparison with public databases has yet to be reported to ensure
a unique signature. Additionally, distribution of these cell lines has been very limited
outside of China.
In 2014, an additional cell line, MDA-ACC-01, was developed from a base of
tongue ACC (64). STR analysis indicated a unique phenotype and early cultures
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proliferated well. However MDA-ACC-01 began to senesce after passage 7, requiring
immortalization with human telomerase transcriptase. Additionally, the properties of
cultured cells may differ from those of the original tumor, with loss of the known MYBNFIB translocation reported in later passages of this cell line (64).

Patient-Derived Xenografts
Several patient-derived xenograft (PDX) models of ACC were developed and
have been distributed to several research groups focused on ACC (65). Patient tumor
tissue was successfully propagated in the subcutaneous flanks of immune deficient nude
mice in 17 of 23 attempts (74%). Tumors were confirmed to be ACC by histologic
analysis, IHC characterization, gene expression profiling, and the detection of the MYBNFIB fusion. Karyotype profiling confirmed that xenografted tumors were derived from
the parent tumor (65).
In addition to serving as reliable preclinical models of disease, xenografts also
serve as a way to expand available tumor tissue, which is particularly useful in rare
cancers like ACC. However, PDX models have their limitations in research, namely
increased maintenance cost, facility space, and distribution difficulty. Furthermore, PDX
models do not offer the same ability to manipulate gene expression or to perform high
throughput screening compared to cell culture.
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Clinical Trials
Systemic Single-Agent Cytotoxics
Because recurrence and metastasis occur frequently despite surgery and radiation,
multiple clinical trials have been undertaken to assess the utility of systemic therapy in
ACC. Despite over 30 phase II clinical trials enrolling patients with ACC since 1985, no
successful single-agent or combinatorial regimens are approved for ACC treatment (32).
Single-agent treatments with traditional cytotoxic drugs have largely failed to
achieve objective responses. In eight trials of single-agent cytotoxic regimens of
gemcitabine (66), paclitaxel (67), cisplatin (68, 69), mitotraxone (70, 71), epirubicin (72),
and vinorelbine (73), major objective responses occurred in 18 of 141 (12.8%) of patients
with recurrent and/or metastatic disease (32). For those cases that did respond to
treatment, durations of response were short, ranging from 5 to 20 months. Of all singleagent therapies, platinum-based regimens with cisplatin were most effective, achieving an
objective response in 2 of 13 patients, though the reported durations of response were a
short 5 and 8 months (69). Disease stabilization was a more common finding in these
trials, reported in 64 of 111 (57.7%) patients (32). However, durations of effect were
again short, with a maximum reported stabilization period of 30 months. Furthermore, in
ACC it can be difficult to distinguish treatment-induced disease stabilization given the
indolent natural course of the disease. In recognition of this point, some trials have begun
documenting ACC progression status before initiation of therapy.
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Combinatorial Cytotoxic Regimens
Combinatorial regimens of traditional cytotoxic agents have also failed to produce
broad sustained effects. A review of 17 trials of combinatorial chemotherapy found that
35 of 143 (24.5%) cases demonstrated an objective response (32). Cisplatin and
doxorubicin were most commonly tested, and they were employed in combination with
cyclophosphamide in four trials (74-77). These trials reported the highest objective
response rates occurring in 9 of 36 (25%) patients; however duration of response was
short, ranging from 5 to 16 months (75, 77). Though results were slightly better than
single agent trials, combinatorial cytotoxic therapy also failed to achieve sustained
responses. Higher rates of toxicity were also seen in combinatorial compared to singleagent therapy (73).
In addition to lack of prolonged response time, another major issue with standard
cytotoxic treatment is the lack of broad effectiveness. Because of the rarity of ACC, large
patient trials are very difficult to organize, and it is thus difficult to perform subset
analyses to reliably identify patient or clinical characteristics predicting response. Despite
failure to induce objective responses, chemotherapeutic agents still play a significant
palliative role in ACC management, with symptomatic relief reported in 30-70% of
single-agent treatments and 25-64% of combinatorial regimens (32).

Molecularly Targeted Therapies
Given the discovery of high c-Kit expression in 90% of ACC tumors, imatinib, a
tyrosine kinase inhibitor (TKI), has undergone multiple trials with the aim of blocking cKit signaling. Six trials of have assessed imatinib activity in a cumulative 71 ACC
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patients, five of which found zero objective responses (49, 50, 78-80) and one of which
saw two objective responses (79). One trial also assessed the effect of adding cisplatin to
imatinib, reporting three patients with partial responses in the combination group versus
none in the imatinib only group (81).
As in other cancers, epidermal growth factor receptor (EGFR) is overexpressed in
ACC and has been correlated with tumor grade (82), prompting the trial of EGFR
inhibitors. Gefitinib, the first inhibitor of EGFR’s tyrosine kinase domain, was studied in
18 patients with recurrent and/or metastatic ACC, but no objective responses were seen
(83). Lapatinib, a TKI targeting EGFR and erbB2, was tested in 19 patients with ACC
positive for EGFR and/or erbB2. No objective responses were reported, but nine patients
(47%) had disease stabilization lasting more than 6 months (84). Cetuximab, a
monoclonal antibody inhibitor of EGFR, was trialed in 23 patients with recurrent and/or
metastatic ACC (85). No responses to therapy were observed, but eight patients (35%)
had a disease stabilization lasting a median time of 4.5 months (85). Another study trialed
cetuximab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy in 12 patients with
metastatic EGFR-positive ACC and cetuximab plus cisplatin with concomitant
radiotherapy in nine patients with locally advanced EGFR-positive ACC (86). Compared
to historical outcomes, results were favorable, with objective responses occurring in four
(44%) patients with locally advanced disease and five (42%) patients with metastatic
disease (86). These results suggest that regimens combining biologic inhibitors, platinumbased chemotherapy, and radiotherapy may be a viable treatment approach in ACC.
Studies of ACC have shown mutations and an overexpression of members in the
fibroblast growth factor receptor (FGFR) signaling pathway (35, 36), warranting testing
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of fibroblast growth factor receptor inhibition. A recent phase II study has assessed the
efficacy of oral dovitinib, a multi-kinase inhibitor of FGFR, vascular endothelial growth
factor receptors (VEGF), and platelet-derived growth factor receptors (PDGFR), in 32
patients with unresectable or metastatic ACC (87). There were no complete responses,
one partial response (3%), and 30 cases (94%) with disease stabilization, though the
authors note that it was difficult to determine if these cases were truly results from
treatment rather than natural disease course (87).
Sunitinib has been another drug of interest, given its ability to inhibit multiple
targets identified as critical in ACC, including c-Kit, VEGF, PDGF, and the RET
oncogene. A phase II study studied the efficacy of sunitinib in 13 patients with
progressive, recurrent, or metastatic ACC (88). Again, however, no responses were seen,
while 11 patients (85%) demonstrated disease stabilization (88).
Bortezimib, an inhibitor of the 26S proteasome and thought to function at least
partially through inactivation of NF-kB, has been studied as a single-agent and in
combination with doxorubicin in a phase II trial of 24 patients with progressive or
metastatic ACC (89). Though well tolerated, no objective responses were seen in either
treatment group, and only one partial response was seen in the combination group (89).
mTOR, a master cell growth regulator and target of PI3K, has been implicated as
an ACC driver and inhibition in preclinical trials have induced cell death in ACC (90),
prompting a phase II study of everolimus, an mTOR signaling inhibitor. Out of 34
patients with progressive unresectable ACC, 27 patients (79%) showed disease
stabilization, however no responses were observed (91). As toxicities were very well
tolerated, mTOR inhibition may play a role in controlling unresectable disease; however,
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the caveat of determining efficacy based on disease stabilization in indolent tumors
remains.

Current Trials
Several preclinical trials have shown promise with regard to potential molecular
targets and are prompting more phase II clinical trials that are currently ongoing. Agents
under investigation include selinexor (inhibitor of CRM, EGFR, HER2, FGFR, c-Kit),
eribulin (inhibitor of mitosis), pembrolizumab (PD-1 inhibitor), and vorinostat (histone
deacetylase inhibitor).
Despite numerous trials with small molecule inhibitors, inducing a reliable
response in ACC remains elusive. While several of the agents studied achieved stable
disease states lasting more than 6 months, more long-term follow up is required to
determine control of late disease progression, given the naturally protracted course of
ACC.
The poor track record of clinical trials using cytotoxic or targeted agents in ACC
likely represents inherent resistance of these cells and point to the inadequacy of preclinical studies to predict response. Clearly, understanding of the true molecular drivers
of ACC remain poor, suggesting that new tools for study and biologic innovation is
needed to make therapeutic advances in ACC. A potentially exciting area of investigation
is the role of Notch in ACC. Building off recent data implicating Notch importance in
ACC (35, 42, 58), three phase I clinical trials studying the efficacy of Notch inhibitors in
ACC are underway (92). One trial is investigating the efficacy of brontictuzumab (OMP52M51), a monoclonal antibody against the Notch1 receptor in refractory and recurrent

19
cases. Two independent trials are assessing the efficacy of BMS-906024, a new panNotch inhibitor, with one study utilizing it as a single-agent and the other in combination
with traditional chemotherapy (92).

Cancer Stem Cells
Cancer Stem Cell Theory
An emerging concept in oncologic treatment is targeting of cancer stem cells
(CSC), a subpopulation of self-renewing tumor cells capable of reinitiating and
recapitulating all cells within the tumor (93). Because radiotherapy and traditional
chemotherapeutics tend to target rapidly proliferating cells, the relatively quiescent state
of CSC may allow them to evade these treatments and thus cause recurrent or metastatic
disease. CSC have been identified in multiple cancers, including myeloid leukemia (94),
HNSCC (95), colorectal (96), pancreatic (97), and neurologic cancers (98). Typical
markers used to identify stem-like cells include aldehyde dehydrogenase 1 (ALDH1)
(99), aldehyde dehydrogenase activity (100), CD44 (95), CD34/CD38 (94), and CD133
(96).

Cancer Stem Cells in ACC
Preliminary evidence suggests that ACC may contain cancer stem cells. One
study isolated cells with high expression of ALDH1 (ALDH1high) from cells with low
expression of ALDH (ALDH1low) in primary ACC tumors and ACC xenografts (101).
Injection of these separated cells into NOD/SCID mice revealed that ALDH1high cells are
more tumorigenic (24 of 60 tumors formed) compared with ALDH1low cells (5 of 126
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tumors formed). Tumors formed from ALDH1high cells maintained histological patterns
reminiscent of clinical ACC specimens (101). Interestingly, ALDH1high cells formed
spheroids characteristic of stem cells seen in other neurologic cancers such as
neuroblastoma (98). Given that ACC highly expresses common stem cell markers and
shares expression profiles with other neurologically based cancers (51), ACC may be
similarly driven by stem cells with neurologic or neural crest properties.

Notch in Cancer Stem Cells
Notch has been identified as a critical mediator of CSC maintenance in many
other cancer types including breast cancer (102), pancreatic cancer (103), embryonal
brain tumors (104), and gliomas (105). The strongest evidence of Notch involvement in
stemness maintenance is seen in breast carcinoma and glioblastoma cell lines, where
blockade of Notch signaling by gamma secretase inhibition decreases the formation of
spheroids containing stem-like cells (105, 106). Notably, gamma secretase inhibition
specifically increases radiation-induced death of glioma CSCs while having relatively
little effect on glioma bulk cells (107). In pancreatic cancer, Notch activation is
associated with gemcitabine-resistant cells (108). These encouraging studies suggest that
targeting of CSCs via Notch inhibition may have a potential role in treatment of
radiation-resistant and chemo-resistant cancers, including ACC.
While still a preliminary hypothesis, the presence of a stem-like population in
ACC may, in part, be responsible for its high rate of recurrence and metastasis. Selective
targeting of critical molecular mediators in this subpopulation may be a promising new
approach in ACC treatment.
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STATEMENT OF PURPOSE
Hypothesis
Salivary ACC contains a subpopulation of cells with neural CSC-like properties
driven by NOTCH1, SOX10, and FABP7 signaling. Inhibitors of Notch signaling may be
effective in preventing CSC growth and radiation resistance, and thus has potential
therapeutic relevance in ACC.

Aims of this Study
1. Establish and validate ACC cell cultures.
Recent studies have found that existing ACC cell lines were contaminated or
misidentified and did not represent ACC (61). We aim to establish and verify new ACC
cultures from ACC xenografts and patient tumors, and if possible establish immortalized
cell lines so that functional experimentation can be performed to better understand ACC
biology.

2. Identify, isolate, and characterize CSC from ACC specimens.
We aim to build on existing studies suggesting the presence of CSC in ACC and
identify markers to distinguish and isolate the CSC population. After isolating this
population of cells, we will characterize their behavior and expression profile to assess
for potential drivers.
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3. Elucidate role of NOTCH and other molecular drivers of CSC in ACC.
We aim to perform functional assays to determine potential roles and interaction
of NOTCH, SOX10, and FABP7 in maintenance of CSC, and the mechanisms by which
these mediators operate.

4. Assess therapeutic role of NOTCH inhibition in ACC.
Based on insights gained from in vitro studies of Notch signaling, we aim to
evaluate the efficacy of Notch signaling inhibitors in the prevention of ACC tumor
growth in culture and animal models. Additionally we assess the effect of Notch
signaling inhibition on the ability of ACC cells to resist radiation.

METHODS
PDX and Primary Tumor Specimens
Validated PDX models of ACC were obtained from Christopher Moskaluk at the
University of Virginia (65). An additional clinical ACC specimen (ACC33) was collected
from the Smilow Cancer Center at Yale New Haven Hospital, obtained through written
patient consent and with approval from the Yale Institutional Review Board (HIC#
1206010419).

Tissue Processing
5-10 mg of fresh or cryopreserved (90% FBS and 10% DMSO) tumor tissue
underwent separate rinses with PBS, 70% EtOH, 100X Anti-Anti (GIBCO), and PBS
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containing 1:500 ceftazidime. Tumor tissue was subsequently minced and transferred to a
15mL plastic tube for digestion at 37ºC for 1-2 hours with occasional agitation. Digestion
mixtures were comprised of 3 mL of complete DMEM media (DMEM with 10% fetal
bovine serum (FBS), 1X Penicillin-Streptomycin, 1X L-Glutamine) supplemented with 1
mL of dispase (BD Biosciences, San Jose, CA), 30-150 µL hyaluronidase (Sigma, St.
Louis, MO), and 30-150 µL collagenase (Roche, Indianapolis, IN). Digested tissue was
collected at 1,500 RPM for 3 minutes, rinsed with PBS, re-centrifuged, transferred into 3
mL of F+Y culturing media (see below), and filtered using a 100 µm cell strainer. Tumor
cells were then transferred to T-12.5 or T-25 flasks, depending on tumor volume, for
culturing. Tumor cells were cultured together with either irradiated 3T3-J2 mouse
fibroblast feeder cells or conditioned media derived from these cells (see below). Tissue
processing was performed by both Michael Chang and Alex Panaccione.

Cell Culture
To establish a reliable ACC culture protocol, we modified a recently published
epithelial cell culturing technique using Rho-kinase (ROCK) inhibitor and irradiated 3T3J2 mouse fibroblasts serving as feeder cells (109). Feeder cells were cultured in complete
DMEM media and grown to confluency in T-175 flasks. Upon reaching confluency, cells
were trypsinzied, washed, collected, and resuspended in fresh complete DMEM media.
Feeder cells were irradiated with 30 Gy, counted, and immediately stored at 4oC for use
up to 36 hours post-radiation. To create feeder cell conditioned media, irradiated 3T3-J2
cells were incubated in a T-150 flask supplemented with 30 mL of DMEM media for 4
days. Media was filter-sterilized and then mixed in a 1:4 ratio with F+Y culturing media.
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F+Y culturing media contained 373 mL DMEM mixed with 125 mL F12 media (Life
Technologies) that contained 7.5% FBS (Life Technologies), 10 ng/µL EGF, 5 µg/mL
insulin (Sigma, St. Louis, MO), 250 µg/mL amphotericin (Fisher Scientific, Pittsburgh,
PA), 10 mg/mL gentamicin (Life Technologies), 8.6 ng/mL cholera toxin (Sigma), and
10 µM Y-27632, a ROCK inhibitor (Enzo Life Sciences, Farmingdale, NY). Cultured
cells were derived from both PDX and patient tumor tissue. Cell culture work was
performed by both Michael Chang and Alex Panaccione.

Microsatellite Analysis
To authenticate cell cultures and cell lines, we used the Promega GenePrint 10
STR analysis PCR kit with fluorescent tagging. PCR products were analyzed on Applied
Biosystems 3730xL DNA Analyzer at the Yale Keck Facility and data was processed
using GeneMapper 3.7 software (Applied Biosystems). The results were cross-referenced
with

publically

available

STR

(http://www.cstl.nist.gov/strbase/,

databases

to

ensure

unique

STR

signature

http://www.dsmz.de/services/services-human-and-

animal-cell-lines/online-str-analysis.html). Microsatellite analysis was performed by Bea
Carbone with assistance from Michael Chang and Alex Panaccione.

Real-time RT-PCR
To assess RNA transcript levels, RNA was isolated from frozen cell pellets of
cells using RNeasy kit (Qiagen, Valencia, CA). cDNA was generated using iScript
Reverse Transcriptase kit (Bio-Rad, Hercules, CA). Quantitative real-time RT-PCR was
performed using iQ SYBR Green Supermix and CFX96 real-time detection system (Bio-
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Rad). β-actin was used as a normalizing control in all experiments. Real-time RT-PCR
was performed equally by Michael Chang and Alex Panaccione.

Western blot analysis
To assess protein expression, western blot experiments were performed with the
following antibodies: SOX10 (Abcam, ab155279), NOTCH1 (Cell Signaling, #3608),
FABP7 (Cell Signaling, #13347), cleaved NOTCH1 (Cell Signaling, #4147), p27Kip1
(Cell Signaling, #2552), SKP2 (Cell Signaling, #4313), β-actin (Santa Cruz, sc-47778),
and GAPDH (Santa Cruz, sc-25778). Pre-cast gels and Rapid Turbo-blot System protein
transferring equipment were purchased from Bio-Rad. Gels were imaged and quantified
using Molecular Imager Gel Doc XR+ System with Image Lab software (Bio-Rad).
Western blot analysis was performed equally by Michael Chang and Alex Panaccione.

Immunofluorescence Staining
Cells were plated onto 8-well glass slides at a density of 25,000-30,000 cells per
well, incubated for 24 h, washed twice with PBS, and fixed with 3-4% paraformaldehyde
at room temperature (RT) for 30 minutes. Cell were permeabilized with 0.15% Triton X100 in PBS for 5 minutes, washed twice, and blocked with 3% bovine serum albumin
(BSA) for 30 minutes. Incubation with primary antibodies diluted in 3% BSA was
performed at 4oC overnight with subsequent washing once with PBS and once with 3%
BSA. The following antibodies were used: SOX10 (Abcam, ab155279), FABP7 (Cell
Signaling, D8N3N), NOTCH1 (Cell Signaling, D1E11), SKP2 (Cell Signaling #4313),
JAG1 (Santa Cruz, C-20), NR2F1 (Santa Cruz, sc-74561) NR2F2 (Parsons Proteomics,
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H7147), and AlexaFluor secondary antibodies (Life Tech). Slides were imaged by
confocal microscopy. Immunofluorescence experiments were performed equally by
Michael Chang, Alex Panaccione, and Bea Carbone.

CSC Isolation
For separation of CD133+ and CD133- cells from bulk cultured cells or digested
PDX tissue, cells were collected by trypsinization, rinsed in PBS, and filtered through a
100 uM cell strainer to obtain a single cell suspension. Cells were labelled with CD133PE antibodies (Miltenyi, San Diego, CA) followed by CD133 Tumor Tissue MicroBead
Kit (Miltenyi). Tumor cells underwent magnetic-activated cell sorting (MACS) by
running through magnetic bead columns provided by Miltenyi. CD133+ and CD133- cells
were collected in separate tubes, and CD133 expression for each was verified using real
time RT-PCR. Based on our experience, MACS is faster and more efficient in sorting
large cell numbers compared to flow cytometry-based sorting methods, and was overall
less harmful to live ACC cells than flow cytometry. CSC isolation was performed
equally by Michael Chang and Alex Panaccione.

Tumorigenicity Assays
All mouse experiments were performed in accordance with NIH national
guidelines and were approved by Yale Institutional Animal Care and Use Committee.
Athymic nu/nu mice were purchased from NCI-Frederick (Frederick, MD). Mice were
injected in the flanks subcutaneously with a specified number of viable tumor cells and
measured weekly for tumor growth. Injected cells were either CD133+, CD133-, or bulk
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tumor cells. Mice were sacrificed at a tumor volume of 1 cm3 or if complications from
tumor burden developed. Statistical analysis for significant differences tumor growth was
performed using the two-tailed t-test. Tumorigenicity assays were performed equally by
Michael Chang and Alex Panaccione.

Immunohistochemical Staining
Tumor tissue was sectioned, fixed, and analyzed by IHC staining using the
following antibodies: cleaved NOTCH1 (Cell Signaling, Val1744), SOX10 (Cell
Marque), and FABP7 (Abcam, Ab32423). IHC staining was performed by Yale Tissue
Services.

Flow Cytometry
To assess effects of RNA knockdowns or DAPT treatment, cells either underwent
DAPT versus DMSO treatment or transfection with siRNA against SOX10, NOTCH1,
and FABP7 versus a control siRNA using lipofectamine in DMEM media. After 48-72
hours, cells were collected and incubated with CD133-PE antibody (Miltenyi) for 10
minutes. Fluorescence-activated cell sorting (FACS) was performed to determine
percentage of CD133+ cells using a FACS Caliber BD machine. Data analysis performed
using Flowing Software version 2.5.0. Flow cytometry was performed equally by
Michael Chang and Alex Panaccione.
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Spheroidogenesis Assay
Cells were seeded in 6-well plates at approximately 50% confluency. Cells were
treated with 1 or 10 µM gamma-secretase inhibitor DAPT (synonyms GSI-IX, LY374973) from MedChem Express (Monmouth Junction, NJ) versus DMSO control, or
using siRNA against NOTCH1, SOX10, and FABP7. At 24-hour intervals, 3 separate
representative digital images per well at 4X magnification were used to quantify spheroid
number. Statistical analysis was performed using a two-tailed t-test. Spheroidogenesis
assays were performed by Michael Chang.

Spheroid Depletion Assay
Cells were seeded in 6-well plates at near-full confluency to allow for spheroid
formation. After growth for 48 hours, cells were treated with varying concentrations of
DAPT versus DMSO control. At 72 hour intervals, 3 separate representative digital
images per well at 4X magnification were used to quantify spheroid number. Statistical
analysis was performed using a two-tailed t-test. Spheroid depletion assays were
performed by Michael Chang.

Cell Proliferation Assay
Cells were cultured in 96-well black clear bottom plates and treated with DAPT
versus DMSO control. After cells were grown for 24-96 hours, viable cells were assessed
by DNA quantification using the Cell Titer Glo system (Promega). Statistical analysis
was performed using a two-tailed student t-test. Proliferation assays were performed by
Michael Chang.
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Cell Cycle Analysis
After treatment with DAPT versus DMSO control or siRNA against SOX10 and
NOTCH1, cells were slowly fixed in 70% cold ethanol and stained with propidium iodide
(PI). A Fluorescence-activated cell sorting (FACS) Caliber BD machine was used to
analyze cells. Data analysis was performed using Flowing Software version 2.5.0. Cell
cycle experiments were performed equally by Michael Chang and Alex Panaccione.

Cell Death Assay
After treatment with DAPT for >72 hours, cells were incubated for 10 minutes
with CD133-FITC antibody (Miltenyi) as well as Annexin V antibody and 7-AAD DNA
stain (Annexin V:PE apoptosis detection kit I, BD Biosciences). A FACS Caliber BD
platform was used and data analysis was performed using Flowing Software version
2.5.0. Cell death assays were performed equally by Alex Panaccione and Michael Chang.

Radiation Sensitivity Assay
Cells were plated in T-25 flasks and irradiated with 3 or 6 Gy using Mark I
Cesium-137 irradiator followed by 48 hours of incubation in the presence or absence of
DAPT. Following treatment, cells were stained with CD133-PE antibody. FACS was
performed to determine percentage of CD133+ cells. Radiosensitivity assays were
performed in triplicate with statistical analysis by a two-tailed student t-test. Radiation
sensitivity experiments were performed equally by Alex Panaccione and Michael Chang.
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In Vivo Testing of DAPT Treatment
In vivo efficacy of DAPT (SelleckChem, Houston, TX) was evaluated in an
Accx11 xenograft model generated via subcutaneous injection of 106 cultured Accx11
cells. Tumor cell-injected mice were randomized into control (vehicle-injected, N=5) and
experimental (DAPT in corn oil, N=5) groups 15 days after cell injection. DAPT was
administered intraperitoneally at 50%mg/kg, following an injection schedule of 3 days of
treatment/4 days rest for 35 days. To assess DAPT toxicity, animals were observed daily
and weighed weekly using a digital scale; data including individual and mean gram
weights, mean percent weight change versus Day 0 and mean percent weight change
versus prior measurement were recorded for each group and plotted at study completion.
To assess DAPT efficacy, tumor dimensions were measured twice weekly by a digital
caliper, and data including individual and mean estimated tumor volumes recorded for
each group. Tumor volume (TV) was calculated using the formula TV=width2 × length ×
0.52. Statistical differences in tumor volume were determined using a two-tailed t-test. In
vivo testing was performed by Alex Panaccione. Tumor processing was performed by
Alex Panaccione and Michael Chang.

RESULTS
Generation and validation of cell cultures from ACC tissue
After the discovery that existing ACC cell lines were either contaminated or
misidentified (61), the generation of new validated ACC cell lines is much needed to
advance studies of this cancer. The rare incidence of ACC, however, limits the amount of
clinical material available for culturing. To overcome this scarcity, we primarily used
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tissue derived from previously verified PDX tumors (65) to generate new ACC cell lines.
Through optimization of a recently published epithelial cell culturing protocol (109), we
successfully generated intermediate- and long-term cell cultures from five ACC
xenografts and one primary ACC tumor, Acc33 (Table 1). Successful cultures were
derived from tumors with a diverse range of grades and histology. All six cultures
proliferated for at least eight passages, with Accx11 and Acc33 reliably proliferating
beyond 30 passages.
Cultures were primarily comprised of adherent spindle-shaped epithelial cells
(Figure 1A). Of note, our most robust culture, Accx11, contained loosely adherent
spheroid aggregates reminiscent of stem cells (Figure 1A, Accx11). All cultures yielded
an adequate amount cells (>106) for molecular studies and cryopreservation.
To confirm the authenticity of newly created cell cultures, microsatellite profiling
of eight sites was confirmed to match parental tumors (Table 2). Microsatellite profiles
between culture and PDX tumors were near identical, with an acceptably small amount of
drift as expected in culture environments. Cross-referencing these microsatellite profiles
with those on publically available databases confirmed that these cell cultures were
unique.

Cultured cells express markers specific to ACC
Previously identified ACC markers were used to validate the identity of cultured
cells. Expression of TrkC/NTRK3, SOX10, NOTCH1, and FABP7 were found nearly
universally in clinical ACC specimens and linked to an ACC-intrinsic gene signature that
contained ~200 genes (51, 52, 110). Reassuringly, real time RT-PCR found that all ACC
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cell cultures expressed high levels all four genes that was higher than levels in normal
salivary gland (NSG) tissue with the exception of NOTCH1 expression in Accx2,
Accx19, and Accx29 (Figure 1B). SOX10, NOTCH1, and FABP7 were similarly found
to be highly expressed in PDX tumors (Supplemental Figure 1). Combining microsatellite
and marker expression verification, these data demonstrate that a ROCK inhibitor- and
cell feeder-based protocol is an effective solution to the ACC cell culture problem, and
that these techniques can be used to advance translational ACC research.

ACC contains CD133+ spheroids that co-express SOX10, FABP7, NOTCH1,
NOTCH1 targets, and neural stem cell markers
SOX10, a key neural stem cell marker, has been identified as signature of stem
cells in cancers originating from neural crest. The SOX10 co-expression profile identified
in ACC (51) suggested existence in ACC of cells with CSC properties. To validate this
hypothesis, we profiled ACC for expression of cell surface markers that could be used for
CSC isolation. Real time RT-PCR revealed that CD133/PROM1 (CD133), a cell surface
marker of neural CSC (111), is expressed in all ACC cultures (Figure 1B) and ACC
xenografts (Supplemental Figure 1).
To better characterize CD133-expressing ACC cells, a robustly proliferating and
spheroid-forming culture, Accx11 was further investigated. FACS analysis of multiple
passages showed that 2-15% of cultured cells expressed CD133 (CD133+) (Supplemental
Figure 2). Magnetic-activated cell sorting (MACS) separation of cultured Accx11 cells
separated CD133+ and CD133- subpopulations as indicated by more than a 50-fold
enrichment of CD133 expression (Figure 2A). Notably, CD133+ cells expressed at least

33
25-fold higher levels of SOX10, NOTCH1, and FABP7 compared to CD133- cells
suggesting that expression of these genes co-segregated with cell surface expression of
CD133 (Figure 2B).
After separation, cultured CD133+ cells generated both spheroid-forming and
tightly adherent cells, while cultured CD133- cells remained adherent and were not able
to produce CD133+ cells or spheroids (data not shown). These data suggest that CD133+,
but not CD133- cells, can reform both cell populations; however contamination of
CD133+ cells with CD133- cells remained a possibility. To further explore stem
properties of CD133+ cells, we investigated the expression of SCRG1, PLP1, MIA,
SHC4, and TTYH1 that are components of the SOX10 co-expressed neural gene
signature in ACC (51). Remarkably and without exception, these genes were more highly
expressed in CD133+ ACC cells compared to CD133- cells (Figure 2B). Given the
association of these genes with stem cells of neurologic cancers (112-115), their selective
expression in CD133+ ACC provide additional support that ACC cultures contain neural
stem-like cells (NSC).
Activation of Notch is a common feature of NSC and CSC (116) and Notch
activation can be determined by levels of the intracellular domain (N1ICD). Western blot
analysis revealed high expression of NOTCH1 and N1ICD in CD133+ compared with
CD133- or unsorted Accx11 cells and confirmed high expression levels of SOX10 and
FABP7 in CD133+ cells (Figure 2C). N1ICD is a marker of NOTCH1 activation as
supported by increased expression of NOTCH canonical downstream targets HEY1,
HEY2, and MYC in CD133+ cells (Figure 2D).

34
To determine if other ACC cultures harbored similar cell populations, cultured
cells derived from an independent xenograft were examined. FACS analyses of Accx19
cells found that 1-8% of total cells were CD133+ (data not shown). MACS separation of
Accx19 cells produced approximately a 3-fold enrichment of CD133 expression in
CD133+ cells compared to CD133- cells. In CD133+ Accx19 cells, expression of
NOTCH1, SOX10, and FABP7 was similarly enriched (Supplemental Figure 3A).
Overall, these data supported the existence of a previously unknown population of cells
in ACC that express both CD133 and SOX10 and contain activated NOTCH1.

CD133 ACC cells express neuronal differentiation markers NR2F1, NR2F2,
−

p27Kip1, and Notch ligand JAG1
ACC

cells

expressing

CD133

expressed

markers

typically

found

in

undifferentiated neural lineage, including NOTCH1 and SOX10. Since cells lacking
CD133 expression expressed much lower levels of markers of stemness, expression of
neural differentiation markers was determined. NR2F1 and NR2F2, two orphan nuclear
receptors important in mediating NSC differentiation (117), were expressed at markedly
higher levels in CD133- ACC cells compared to CD133+ cells (Figure 2E), suggesting
that ACC cells lacking CD133 expression represent a more differentiated cell population.
Finding neural differentiation markers in CD133- cells suggests that these more
differentiated cells may have arisen from CD133+ ACC cells that express markers of
neural stemness.
JAG1, a canonical Notch ligand, is an activator of Notch signaling, and in many
cancers it is expressed not in stem cells but in supporting niches (118, 119). Interestingly,
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JAG1 expression was markedly higher (~11-fold) in Accx11 CD133- cells (Figure 2E).
Similarly, NR2F2 and JAG1 were also expressed predominantly in CD133- cells isolated
from Accx19 cultures (Supplemental Figure 3B).
p27Kip1 is a cyclin-dependent kinase inhibitor that results in proliferative arrest
and is a critical effector of neural differentiation whose expression is inhibited by
activated NOTCH1 in NSC (120, 121). Given that in Accx11 cells NOTCH1 is
preferentially activated in CD133+ cells (Figure 2C) and that CD133- cells express
markers of neural differentiation (Figure 2E), expression of p27Kip1 was measured in
both ACC populations. Immunoblotting of unsorted and CD133- Accx11 cells after
sorting revealed significantly higher p27Kip1 levels compared to the CD133+ population
(Figure 2F).

Immunofluorescence analysis confirms unique molecular profiles of CD133+ and
CD133- cells and supports NOTCH1/JAG1 interaction
RNA and protein expression analysis suggest that two previously unknown and
distinct subpopulations within ACC can be reliably identified using a series of molecular
markers. Based on selective expression of NOTCH1 and its targets in CD133+ cells and
JAG1 in CD133- cells, a model of inter-population signaling via NOTCH1/JAG1
interaction is proposed (Figure 2G). Immunofluorescence staining of cultured Accx11
cells supported this hypothesis with NOTCH1, SOX10, FABP7, and cell surface CD133
staining detected in a distinct cell population associated with less firmly attached cells, or
spheroids, and NR2F1, NR2F2, and JAG1 detected in adherent cells. CD133
immunofluorescent staining was detected on a minority of cells within loosely adherent
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cells that stained uniformly with NOTCH1 antibody, while the differentiation marker
NR2F1 was detected only in the cytoplasm of adherent and more fusiform cells (Figure
2H and 2I). Differentiation markers NR2F1 (cytoplasmic) or NR2F2 (nuclear) were
present in the attached cell population, but below the level of detection in less adherent
spheroids (Figure 2I, 2J, and 2K). Remarkably, NOTCH1-expressing cells within
spheroids were closely surrounded by adherent cells expressing membrane-localized
JAG1 (Figure 2L). Z stack images revealed that JAG1 and NOTCH1 were co-localized
on adjacent surfaces of cells within adherent and spheroid cells, respectively (Figure 2L,
see arrows). Combined, these data support the existence of two cell subpopulations in
ACC, one being more stem-like with expression of SOX10 and NOTCH1 and one being
more differentiated. A co-dependence of these cell populations is possible given the
expression of JAG1 on more differentiated CD133- ACC cells and its receptor, NOTCH1,
on CD133+ stem-like cells.

CD133+ and CD133- populations identified in grafted ACC tissue
To determine if subpopulations of differentiated and stem-like cells exist more
generally in ACC and to validate in vitro findings, CD133 expression was determined in
a series of ACC patient-derived xenografts and markers of stemness and differentiation
correlated. After dissociation and MACS sorting of five ACC PDX tumors, cell counting
of viable cells found CD133 expression in 21 to 65% of cells (Figure 3A). Real-time PCR
revealed that CD133+ cells generally expressed higher levels of SOX10, NOTCH1, and
FABP7 (Figure 3B, 3C, 3D, 3E). CD133- cells universally expressed higher levels of
JAG1 with more variable expression level of NR2F1 (Figure 3F and 3G). These results
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mirrored our findings in cultured cells, confirming the existence of two cell populations
in ACC defined by expression phenotypes, SOX10+/NOTCH1+/FABP7+/CD133+ and
JAG1+/NR2F1+/ CD133-.

Tumorigenicity of ACC subpopulations
The ability of cultured ACC cells to initiate tumors was investigated via
subcutaneous injections of 106 cells into shoulder flanks of nude mice. Among ACC
cultures tested to date, only Accx11 cells were tumorigenic in nude mice, forming tumors
with solid histology and an intervening stromal component histologically similar to the
parental patient tumor and PDX (Figure 4A). Relative expression of CD133, SOX10,
NOTCH1, and FABP7 was similar in the original PDX and in the tumor produced from
injection of cultured cells and higher than NSG as measured by RT-PCR and confirmed
in tumor tissue by immunoblotting (Figure 4B and 4C).
In various cancer types, CD133 expression defines populations of CSC with
enhanced tumor-initiating properties (122). To investigate CSC properties of CD133expressing ACC cells, bulk Accx11 tumor cells were separated based on CD133
expression by MACS and 104 cells were injected subcutaneously into right (CD133+) and
left (CD133-) flanks of three nude mice. After 22 weeks, tumors were observed in 3 of 3
sites injected with CD133+ cells, but in none of 3 sites injected with CD133- cells. At 32
weeks, a single tumor formed at a site injected with CD133- cells. Histologic evaluation
of the parental ACCX11 tumor, tumors derived from CD133+ cell injections, and the
single tumor from a CD133- cell injection revealed similar histologic appearance
(Supplemental Figure 4A). Expression analyses of CD133, SOX10, NOTCH1, and
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FABP7 by real-time PCR and immunoblotting revealed expression of all markers in
tumors derived from both CD133+ and CD133- cells (Supplemental Figure 4B and 4C)
suggesting that injected CD133- populations can convert to CD133+ populations, or that
separation of CD133+ and CD133- cells was incomplete.
As experience with CD133 cell separation increased, we found that a single round
of separation using CD133 antibody conjugated to beads left detectable traces of CD133+
cells in the CD133- population, reflecting technical limitations of this procedure. Also,
separation decreased viability of CD133+ cells more than CD133- cells, possibly due to
the damage inflicted by mechanical elution of column-bound cells (data not shown). To
more adequately compare tumorigenicity of CD133+ and CD133- cells, a second round of
magnetic separation was performed on the unbound cells to isolate a more pure CD133population. Following this double separation, 105 viable cells of each population were
injected into the flanks of nude mice. Tumors began to form at the sites of CD133+
injections as early as 6.5 weeks after injection. By 13 weeks post-injection, 4 of 5
CD133+ injection sites had distinct tumors while none of 5 CD133- injections showed
signs of tumor formation. Mean tumor volumes at 13 weeks were 0.14 cm3 for tumors
derived from CD133+ and 0.01 cm3 for tumors derived from CD133- cells (Figure 4D)
(p<0.05). With a marked delay, 2 of 5 injection sites of CD133- cell injections formed
small tumors with the earliest tumor developing at 19 weeks. At 27.5 weeks, 5 of 5
CD133+ injection sites formed tumors, while no additional tumors grew in CD133injection sites. Overall, these experiments demonstrated enhanced tumorigenicity of
CD133+ cells compared to CD133- cells.
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Interdependence between NOTCH1, SOX10, and their common effector FABP7
Essential individual roles for SOX10 and NOTCH1 in NSC maintenance are well
established, and loss of Notch signaling decreases SOX10 expression in neural
progenitors (123, 124). FABP7 has recently been described as critical for proliferation
and prevention of differentiation in neural progenitors (125) and as a marker of
aggressive clinical behavior in ACC (52). Given that SOX10, NOTCH1, and FABP7 are
each implicated in neural stemness, their interdependence in ACC cells was studied.
Following individual knockdowns, expression of all three genes was measured by RTPCR and immunoblotting. Depletion of SOX10 markedly decreased NOTCH1 expression
and, reciprocally, knockdown of NOTCH1 was associated with decreased SOX10 both at
the RNA and protein levels (Figure 5A and 5B). As expected, since FABP7 is a common
target of NOTCH1 and SOX10 (56, 126), depletion of either NOTCH1 or SOX10
markedly suppressed FABP7 RNA and protein levels. Interestingly, knockdown of
FABP7 also had suppressive effects on RNA levels of NOTCH1 and SOX10. At the
protein level, FABP7 had no obvious effect on NOTCH1 expression while modestly
decreasing SOX10 levels (Figure 5A and 5B). These data suggest the interdependence
and potential functional cooperation of SOX10, NOTCH, and FABP7.
Although individual roles of NOTCH1 and SOX10 in CSC and NSC survival are
well established, their roles in ACC, as well as co-operation via FABP7 and possibly
other effectors has not yet been studied. To begin exploring the role of FABP7 in ACC
signaling, gene expression profiling was performed in Accx11 cells following FABP7
depletion. Analyses revealed that 1158 genes were downregulated, and KEGG pathway
analysis (http://bioinfo.vanderbilt.edu/webgestalt/) implicated these genes in cell cycle
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regulation, ribosome biogenesis, cell metabolism, and signaling pathways regulating
these processes (Table 3). Among these genes, 11 belonged to the Notch signaling
network and 26 genes overlapped with the ACC SOX10 gene signature that we
previously characterized (51). This observation further supported the feedback signaling
from FABP7 to NOTCH1 and SOX10. In addition, SKP2, a major NOTCH1 effector
involved in the regulation of cell cycle and proliferation (127), was among 31 cell cycle
progression and 11 NOTCH1-regulated genes downregulated by FABP7 knockdown. In
summary, these data suggested that NOTCH1, SOX10, and FABP7 may be co-regulated
in ACC, and that FABP7 may serve as a pro-survival NOTCH1 and SOX10 effector.

SOX10, NOTCH1, and FABP7 are required for spheroidogenesis
NSC and CSC have the propensity to form spheroids in culture (128). Using
spheroid formation as a surrogate of stem cell survival and proliferation, functional
consequences of SOX10, NOTCH1, and FABP7 knockdowns were determined.
Individual depletion of these genes significantly suppressed spheroid formation in
cultured Accx11 cells (Figure 5C and 5D). These data suggested that SOX10, NOTCH1,
and FABP7 are vital for spheroid formation, which could be due to a role in CSC survival
and growth. Flow cytometry analysis of Accx11 was performed to assess the effects of
SOX10, NOTCH1, and FABP7 depletion on cell cycle progression and cell survival. A
marked (~4-6-fold) increase in the sub-G1 populations, indicating cell death, was
observed following NOTCH1, SOX10, or FABP7 depletion (Figure 5E). Taken together,
these results suggested that NOTCH1, SOX10, and FABP7 are important for survival of
ACC cells, cell cycle progression, and maintenance of the stem-like subpopulation.
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NOTCH1 depletion and gamma-secretase inhibition decrease CD133+ cells
To test whether NOTCH1 is required for CD133+ survival, the percentage of
CD133+ cells was measured following NOTCH1 knockdown in bulk Accx11 cells.
NOTCH1 depletion resulted in a ~2.5-fold decrease in the proportion of CD133+ cells
(Figure 6A). Pharmacologic inhibitors of SOX10 and FABP7 are not available for
clinical use at this time, however Notch signaling inhibitors are available in the form of
gamma-secretase inhibitors that have advanced to clinical trials (129). Bulk Accx11 cells
treated with gamma-secretase inhibitor, DAPT, suppressed spheroid formation in a
concentration-dependent manner (Figure 6B and 6C). To determine if Notch signaling
was also required for maintenance of pre-formed spheroids, Accx11 was grown to
confluency to allow spheroid formation. Over a 9-day time course, a dose-dependent loss
of pre-formed spheroids was observed in DAPT-treated Accx11 cells compared to
controls (Figure 6D); however, the effect of gamma-secretase inhibition on maintenance
of preformed spheroids was not as dramatic as its effect on spheroidogenesis and
plateaued after six days.
To determine if DAPT activity was selective for CD133+ cells, ACC cells were
separated by MACS then treated with DAPT for 72 hours. DAPT treatment suppressed
proliferation of CD133+ cells with significant differences noted at all doses (1, 5, and
10µm), while proliferation of CD133- cells was not affected (Figure 6E). FACS analysis
confirmed a selective DAPT effect, demonstrating a ~2.5-fold increase in sub-G1
population in CD133+ cells without altering cell cycle progression in CD133- cells
(Figure 5F), suggestive of selective cell death in the CD133+ population. Annexin and 7AAD co-staining confirmed that DAPT treatment selectively killed CD133+ cells.
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(Supplemental Figure 5). Interestingly, the pattern of cell death differed from that seen in
apoptosis, suggesting an alternative cell death pathway induced by DAPT. Taken
together, these data suggest that Notch signaling is critical in the proliferation and
survival of CSC in ACC.

Notch signaling inhibitors prevent ACC tumor growth in mice
To perform a preclinical assessment of DAPT as a single agent treatment in ACC,
Accx11 cells were injected subcutaneously into nude mice followed by 35-day treatment
of peritoneally administered DAPT versus a vehicle control. In this study, DAPT had a
statistically significant tumor-suppressive effect starting at two weeks (Figure 6G)
without obvious signs of toxicity or loss of mouse weight. Overall, these in vitro and in
vivo data suggest that Notch inhibitors could be advanced to clinical studies as a singleagent therapy for ACC.

Notch inhibition increases radiation sensitivity of CD133+ cells
Because CSC are implicated in radiation resistance in many tumor types (122),
the effect of targeting CD133+ cells through Notch inhibition in combination with
radiation was determined by treating cells with DAPT for 24 hours before irradiation.
Radiation alone had minimal effect on the proportion of CD133+ cells with 6 Gy of
radiation decreasing this fraction only moderately, from 2.7 to 2.3%, (~15%) (Figure
6H). However, DAPT as a single agent showed a two-fold (~56%) decrease in the
proportion of CD133+ cells. Remarkably, when a single 3 Gy or 6 Gy dose of radiation
was added to DAPT treatment, the combined effect resulted in an almost 2-fold
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enhancement of CD133+ cell depletion as compared with DAPT alone. DAPT induced
statistically significant (p<0.05) depletion of CD133+ levels at each dose of radiation
when compared to radiation alone. The enhanced loss of CD133+ ACC cells following
radiation in the presence of DAPT suggest that Notch inhibitors may have a role in
sensitization of ACC cells to radiation.

NOTCH1 depletion down-regulates SKP2, an E3 ubiquitin ligase that controls
p27Kip1
Activated NOTCH1 reduces p27Kip1 levels by stimulating expression of the
p27Kip1 E3 ubiquitin-ligase, SKP2 (130). Identification of SKP2 downstream from a
NOTCH1 effector, FABP7, suggested that SKP2 and p27Kip1 may be engaged in the
survival and proliferative NOTCH1 signaling in stem-like ACC cells. Indeed, we
observed decreased expression of p27Kip1 in CD133+ Accx11 cells, where NOTCH1 was
activated (Figure 2C and 2F). Assessment of SKP2 expression by RT-PCR and
immunoblotting showed enrichment of SKP2 in CD133+ compared to CD133- cells
(Figure 7A and 7B). Immunofluorescent staining of Accx11 cultures revealed that SKP2
was detected primarily in NR2F1-negative spheroidal cells, and was localized within the
cytoplasm (Figure 7C), where it has been associated with oncogenic activity (131). Since
SKP2 is a NOTCH1 transcriptional target, inhibition of NOTCH1 activity is expected to
suppress SKP2 expression and, in turn, increase p27Kip1 protein stability and levels. In
agreement with these expectations, siRNA-mediated NOTCH1 knockdown dramatically
decreased SKP2 mRNA levels in Accx11 cells, as did DAPT treatment in a dosedependent manner (Figure 7D and 7E). To determine if Notch effects on SKP2 and
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p27Kip1 are CD133+-selective, bulk Accx11 cells, CD133+, and CD133- populations were
treated with DAPT for 48 hours then cell lysates subjected to immunoblot analysis. As
expected, CD133+ cells expressed higher levels of N1ICD than bulk or CD133- cells, and
DAPT effectively inhibited NOTCH1 activation as marked by decreased N1ICD in these
cells (Figure 7F). SKP2 was readily detected in only CD133+ cells, whereas p27Kip1 was
detected in CD133- cells at much higher levels than in CD133+ cells. Treatment with
DAPT did not markedly alter expression of p27Kip1 in bulk or CD133- cells, but
dramatically enhanced its expression in CD133+ cells (Figure 7F). Together, these data
suggest a possible mechanism by which NOTCH1 inhibition decreases oncogenic activity
in ACC is through downregulation of SKP2 and upregulation p27Kip1 selectively in
CD133+ cells.

DISCUSSION
The significance of these studies lies partially in their ability to provide a
framework and tools to begin addressing many of the current difficulties in ACC
research. Advancements at both the basic science and clinical level include creation of
validated cell cultures lacking widespread contamination previously observed in ACC
cell lines (61) and providing a platform for pre-clinical studies to avoid continued high
failure rates of clinical trials for systemic therapies in ACC (32). We demonstrate a new
and effective method for culturing ACC cells from PDX and patient tumors, enabling
functional experimentation and in-depth study of ACC biological drivers.
While CD133 expression was recently reported in ACC (132), there have been no
published attempts to isolate and characterize CD133+ ACC cells. Techniques described
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here were used to isolate an enriched CD133+ population and characterize gene
expression within this ACC subpopulation. Expression of SOX10, NOTCH1, FABP7,
and multiple key neural stem cell regulators along with their potent tumor-initiating
activity suggest that CD133+ expression marks a neural stem-like population of cells
within ACC. Furthermore, we demonstrate a role of SOX10, NOTCH1, and FABP7 for
proliferation and radiation resistance of CD133+ cells, identifying new potential pathways
to target in ACC treatment. It will be interesting to determine if other molecular defects
in ACC, including MYB fusions, are also involved in ACC stem cell survival or
maintenance. Treatment for this cancer is in much need of a novel approach, and
selective targeting of CSC may address issues of recurrence and relentless growth even
after radiotherapy.
Gene knockdown studies highlighted the essential roles and potential functional
cooperation between NOTCH1 and SOX10 in maintenance of CD133+ ACC cells. An
important and previously unappreciated insight into this cooperation was provided by the
co-expression and interdependence of FABP7 with NOTCH1 and SOX10, as well as the
role of FABP7 in regulating expression of genes critical for cell survival. FABP7 has
been recently described as a novel diagnostic and prognostic ACC marker (52) and is also
implicated in glioblastoma, melanoma, and basal-like breast cancer (53, 133, 134);
however, its downstream targets and molecular mechanisms of activation have not been
extensively studied. Data presented herein associated FABP7 with the expression of
SKP2 and multiple other genes involved in survival, proliferation, and metabolic
pathways identifying a novel signaling pathway that stimulates CSC in ACC.
Importantly, these findings may extend beyond ACC to other cancers of neural origin in
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which SOX10/NOTCH1/FABP7 signaling may also have crucial driving roles and
therefore therapeutic relevance.
As multiple Notch inhibitors have recently entered clinical trials for ACC, the
findings of our study support the rationale behind these investigations. We demonstrate
that a gamma secretase inhibitor selectively triggers cells death in tumor-initiating cancer
stem cells, suggesting that Notch inhibitors have potential therapeutic roles in
monotherapy or as an adjunct to initial surgery to prevent recurrence. Additionally, we
demonstrate that CSC in ACC are sensitized to radiation when treated with a gamma
secretase inhibitor, suggesting that Notch inhibitors may also have a significant
neoadjuvant or adjuvant treatment role with radiation.
Notch targeting with gamma-secretase inhibitors in trials for other cancers have
been largely plagued by severe gastrointestinal side-effects attributed to the broad offtarget effects of gamma secretase inhibition. This has prompted the development and
clinical testing of more specific inhibitors of Notch signaling, which include monoclonal
antibodies against specific Notch receptors such as tareztumab (anti-Notch2/3) and
brontictuzumab (anti-Notch1) as well as antibodies against activating ligands of Notch
such as demcizumab and OMP-305B83 (both anti-DLL4) (OncoMed). Brontictuzumab is
one of the drugs currently under investigation in a phase I trial for ACC. Multiple other
small molecule inhibitors of the Notch pathway are in preclinical development.!
In this study we have also identified other potential therapeutic targets that can be
the subject of future studies. Detection of JAG1 expression on the surface of CD133ACC cells provides an important insight into evolutionary conserved molecular
mechanisms of communication between CD133- and CD133+ cells. Since JAG1
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expression in cancer has been linked to angiogenesis, chemoresistance, and poor survival
(118), JAG1 targeting may provide additional means for therapeutic interventions aimed
at both CD133- and CD133+ cell populations.
Association of NOTCH1 activation with SKP2 and p27Kip1 provided an
interesting insight into CSC-specific signaling in ACC. In addition to its central roles in
the regulation of proliferation, apoptosis, and senescence, which are mediated via p27Kip1
(135), SKP2 is critically involved in tumor survival during energy stress (136, 137).
SKP2 functions at a crossroad of many oncogenic signaling axes, suggesting that SKP2
inhibitors may increase efficacy of future CSC-targeting ACC therapies when used in
combination with Notch inhibitors.
It is important to recognize the limitations of this study. Given the rarity and
unpredictability of cancer, it is difficult to assess generalizability of our findings to all
cases of ACC, as the majority of our in vitro investigations were performed in one or two
cell lines, Accx11 and Accx19. However, our immunomagnetic sorting and expression
analysis of all available patient-derived xenograft tumors suggest that CD133+ cells
expressing a similar expression profile are found in the majority of ACC specimens, and
that all tested ACC tumors from patients expressed a neural stem gene expression pattern
based on SOX10 (51). Future studies should aim to perform these experiments in other
cell cultures and lines to determine the external validity of our findings. Additionally,
while microsatellite analyses show little drift from xenograft to tumor, all cultures
derived from PDX tumors may have already selected for the most robustly proliferating
cells. While we did have success in establishing one culture directly from tumor tissue,
these efforts will need to be continued in the future to ensure that cultured cells represent
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clinical specimens as reliably as possible. In our treatment of ACC cells, we recognize
that gamma-secretase inhibitors are known to have several off-target effects in addition to
interference with Notch signaling. Observation of similar outcomes with depletion of
NOTCH1 was reassuring that the biologic response to gamma secretase activity was
mediated largely through NOTCH inhibition, but animal studies could not be performed
with more specific NOTCH inhibition. Therefore, some assays may have been
unknowingly altered by off-target effects of gamma secretase inhibition, and future
studies are needed with more specific Notch inhibitors to clarify the precise role of Notch
in CD133+ cell maintenance and radiation resistance.
Overall, characterization of neural stem-like cells in ACC and delineating
signaling events essential for their maintenance provide a new concept for ACC treatment
that focuses on the clinical significance of cancer cells with neural stem properties.
Continued study into the characteristics of this newly identified subpopulation of cells
has the potential to open additional therapeutic opportunities for a relentless cancer that
greatly needs new approaches.
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Figure 1. Cytological and molecular properties of ACC cell cultures.
(A) Low and high magnification brightfield images of cultured ACC cells at indicated passages for Accx5m1, Accx11, Accx19, and Acc33.
(B) Real-time PCR quantification (RT-PCR) of gene expression for SOX10, NOTCH1, FABP7, NTRK3/TrkC, and PROM1/CD133 in
cultured ACC cells compared to cultured cells isolated from normal salivary gland (NSG). In all RT-PCR experiments, expression is
normalized to β-actin and error bars show standard errors representative of at least two independent experiments.
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Figure 2. Isolation and characterization of CD133+ and CD133- cells in Accx11 culture.!
(A) RT-PCR of CD133 expression in Accx11 cell fractions following magnetic-activated cell sorting (MACS). !
(B) Expression analysis by RT-PCR of ACC-associated (SOX10 & FABP7) and NSC-associated (NOTCH1, SCRG1, PLP1, MIA, SHC4,
& TTYH1) genes in MACS-sorted Accx11 cell fractions. !
(C) Immunoblot analysis shows selective expression of SOX10, NOTCH1, activated intracellular domain of Notch-1 (N1ICD), and FABP7
in CD133+ cells. β-actin serves as a loading control.!
(D) Expression analysis by RT-PCR of Notch targets MYC, HEY1, and HEY2 in MACS-sorted Accx11 cell fractions. !
(E) Expression analysis by RT-PCR of JAG1 and neural differentiation markers NR2F1 and NR2F2 in MACS-sorted Accx11 cell fractions.!
(F) Immunoblot analysis of CD133 fractions demonstrates CD133- cell-specific p27Kip1 expression. β-actin serves as a loading control.!
(G) Molecular determinants of stem-like CD133+ cells and more differentiated CD133- cells.!
(H-L) Immunofluorescence staining demonstrates great selectivity of CD133+ and CD133- cell markers and confirms spheroid-forming
property of CD133+ cells. Z-stack images (L) show NOTCH1 and JAG1 co-localization at sites of spheroidal and non-spheroidal cell
contacts (arrows).!
!
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Figure 3. Isolation and characterization of CD133 fractions from
ACC xenografts.
(A) Variation in the percentage of CD133+ cells across ACC
xenografts.
(B) RT-PCR analysis of CD133 expression confirms adequate
separation of CD133+ and CD133- cells isolated from ACC
xenografts.
(C-E) Selectivity of SOX10, NOTCH1, and FABP7 to CD133+ cells
isolated directly from ACC xenografts as confirmed by RT-PCR.
(F, G) Selectivity of JAG1 and NR2F1 to CD133- cells isolated
directly from ACC xenografts as confirmed by RT-PCR.
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Figure 4. Tumorigenic properties of bulk and CD133-fractionated Accx11 cells.
(A) Cultured bulk Accx11 subcutaneously injected in athymic nude mice produce tumors with histology similar to patient tumor and parental
xenograft (H&E staining).
(B) CD133, SOX10, NOTCH1, and FABP7 expression compared with normal salivary gland tissue (NSG) confirms ACC identity of PDX
tumors and tumors generated from injection of bulk Accx11 cells.
(C) Immunoblot analysis confirms similar expression of SOX10, NOTCH1, and FABP7 in PDX and tumor formed from injected bulk Accx11
cells. GAPDH serves as a loading control.
(D) Dot plot of tumor volumes 13 weeks after injection of 105 CD133- or CD133+ MACS-sorted Accx11 cells.
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Figure 5. Interrelated stimulatory effects of SOX10, NOTCH1, and FABP7 on ACC cells.!
(A) RT-PCR analysis of SOX10, NOTCH1, and FABP7 expression following siRNA knockdowns reveals their regulatory
interdependence. !
(B) Validation of SOX10, NOTCH1, and FABP7 interdependence by Western blot. β-actin serves as a loading control. !
(C) Depletion of SOX10, NOTCH1, and FABP7 by siRNA suppresses spheroidogenesis of Accx11 cells at 72 hours. Arrows:
brightfield images of spheroids. !
(D) Quantification of suppressive SOX10, NOTCH1, and FABP7 knockdown effects on spheroids compared to untreated Accx11 cells.
Error bars represent standard errors and are representative of at least two independent experiments. In each case, siRNA knockdown
resulted in a significant decrease in spheroid formation (p<0.001, Student’s t-test).!
(E) Suppression of SOX10, NOTCH1, and FABP7 by siRNA increases sub-G1 cell population indicative of cell death. Histograms
represent cell counts based on propidium iodide (PI) staining of Accx11 cells. Percentages of live cells in different cell cycle phases are
shown. !
!
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Figure 6 (cont.)
Figure 6. Inhibition of Notch signaling selectively depletes
CD133+ cells.!
(A) Suppression of NOTCH1 signaling by siRNA decreases the
CD133+ cell fraction (red) as demonstrated by FACS analysis
using PE-conjugated CD133 antibody. !
(B) Inhibition of Notch signaling with gamma-secretase
inhibitor DAPT demonstrates dose-dependent suppressive
effects on spheroid formation (arrows) in Accx11 culture at 48
hours.!
(C) Quantification of DAPT effects on spheroid formation
compared to control (DMSO-treated) Accx11 cells. !
(D) Breakdown of pre-formed spheroids induced by DAPT as
shown by quantification of remaining spheroids following
DAPT treatment versus control (DMSO-treated) Accx11 cells. !
(E) Inhibitory DAPT effect on cell proliferation is highly
CD133+-selective and dose-dependent. At 72 hours, there is a
statistically significant decrease (p<0.01) in luminescence (Cell
Titer Glo assay).!
(F) DAPT selectively induces cell death in the CD133+
population as demonstrated by increase in sub-G1 cell
population. Histograms represent cell counts based on PIstaining of separated Accx11 cells. p<0.05 (*), p<0.01 (**),
p<0.001 (***), two-tailed t-test. !
(G) Suppressive effect of DAPT on tumor growth in a nude
mouse model subcutaneously injected with Accx11. Starting at
week 2, p<0.01. !
(H) Combination of DAPT with radiation is more detrimental to
CD133+ cells (red) than DAPT or radiation alone.
Representatives of 3 replicates are shown (p<0.05 in all
comparisons except 3 Gy vs 6 Gy, radiation only). FACS
analysis was performed with PE-conjugated CD133 antibody. !
!
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Figure 7. CD133+-cell-selective and NOTCH1-dependent
SKP2 expression in ACC cells.
(A-C) SKP2 is selectively expressed in CD133+ Accx11 cells
as demonstrated by RT-PCR (A), immunoblot (B), and shows
cytoplasmic localization in spheroid-forming CD133+ cells as
demonstrated by immunofluoresence (C). β-actin serves as a
control for (A) and (B).
(D-E) Inhibition of Notch signaling by siRNA (D) and DAPT
(E) decreases expression of SKP2 in bulk Accx11 cells (RTPCR).
(F) DAPT blocks expression of activated NOTCH1 (N1ICD)
and its target SKP2 in CD133+ ACC cells and up-regulates
p27Kip1, a SKP2 substrate. β-actin serves as a loading control.
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Supplemental Figure 1. Expression of SOX10, NOTCH1, FABP7, and CD133 in ACC tumor specimens from patients (P) and PDX (X).
The comparison is based on previously produced Affymetrix data (110).
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Supplemental Figure 2. FACS analysis of Accx11 cells stained with PE-conjugated CD133 antibody.
CD133+ cells (red) comprise ~12.4% of the bulk population.
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Supplemental Figure 3. FACS analysis of Accx19 cells stained with PE-conjugated CD133 antibody.
Expression analysis of Accx19 cultured cells by RT-PCR demonstrates enrichment of CD133+ markers (A) and CD133- markers (B), similar to
the pattern seen in Accx11 cells. Expression is normalized to β-actin and error bars are standard error representative of at least two
independent experiments.
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Supplemental Figure 4. Tumors formed from injected Accx11 CD133- cells closely parallel tumors formed from injected
CD133+ cells.
Analysis of histological grade by H&E staining (A), gene expression by RT-PCR (B), and protein expression by immunoblot (C). βactin serves as a control for all experiments. Error bars represent standard error representative of at least two experiments.
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Supplemental Figure 5. DAPT selectively increases cell death in CD133+ Accx11 cells as shown by PE-annexin and 7-AAD
double staining.
DMSO treatment serves as a control.
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Cell Culture ID
Accx5m1
Accx11
Accx14
Accx19
Accx29
Acc33

Tumor grade
2M
3
1
2
1
2

Histology
Cribriform
Solid
Cribriform
Cribriform
Unknown
Cribriform & Tubular

Table 1. Characteristics of ACC cultures and their parental tumors.

Table 1

Max Passage
8
>30
15
10
18
>30

Doubling Time (hrs)
77
29
96
86
60
84
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Table 2. Validation of ACC cell culture via microsatellite analysis of eight STR sites.!

Table 2
74

Table 3
Table 3. Genes and pathways suppressed by FABP7 knockdown in Accx11 cells.
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